Sight Sciences Inc. (SGHT) recently reported positive outcomes from an investigator-led trial of their TearCare treatment, emphasizing improvements in both functional visual outcomes and the alleviation of signs and symptoms in patients suffering from dry eye disease.
The study, which was prospective and conducted at a single center, assessed the effect of TearCare treatment on clinical outcomes, vision-related quality of life, and functional visual metrics in patients with dry eye disease linked to meibomian gland disease.
Significant enhancements were noted in reading speed and vision-related life quality, highlighting the benefits of this interventional treatment for dry eye patients. Specifically, the study found that 52% of participants experienced a clinically notable increase in reading speed post-TearCare therapy, marked by a rise of over 10 words per minute in the International Reading Speed Texts (IReST) score. Both the IReST and the Minnesota Low Vision Reading Test (MNREAD) indicated statistically significant improvements.
Furthermore, scores from the Ocular Surface Disease Index (OSDI) and the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25), which assess symptoms and quality of life related to vision, showed marked enhancements following the TearCare intervention. In addition, all measured metrics of dry eye disease signs improved significantly, including tear break-up time, meibomian gland secretion scores, and corneal fluorescein staining results.
On the financial front, SGHT shares closed at $6.18 on Monday, marking an increase of $0.44 or 7.67%.
